Abstract
Currently, there is an urgent need to develop genetically engineered multivalent subunit vaccines or DNA vaccines to provide protection against infection of multiple types of Clostridium perfringens bacteria. Toward this end, in this study, a set of molecular biotechnologies were used to efficient express and obtain soluble fusion protein of alpha-beta1-beta2-epsilon-toxin (α-β1-β2-ε-toxin) derived from C. perfringens in Escherichia coli. A soluble fusion protein of α-β1-β2-ε-toxin was obtained for the first time with efficient expression in Escherichia coli system by conducting codon optimization, removing the signal peptide, selecting sequences of higher hydrophilicity and antigenicity, removing the lethal gene and optimizing the expression conditions. Noticeable rise of antibody level was detected in the serum of mice after immunization with the expressed protein. The survival rate of the immunized mice during the 7-day challenge period was 100% in the cases of C. perfringens types A, B, C and D.
Introduction
Clostridium perfringens is a versatile and dangerous pathogen responsible for devastating intestinal diseases in livestock, such as enterotoxemia and "braxy," leading to significant economic losses. In humans, it is a primary cause of food poisoning and gas gangrene. Traditional "toxoid" vaccines, which use inactivated toxins, often suffer from stability issues, inconsistent safety profiles, and significant side effects.
Subunit vaccines, which use specific parts of the toxin, offer a safer alternative. However, producing these proteins in Escherichia coli often results in the formation of insoluble, inactive inclusion bodies, complicating purification and efficacy. This study addresses these challenges by engineering a single, soluble fusion protein that targets four major C. perfringens toxins simultaneously.
Methods
The researchers developed a multivalent vaccine candidate using several molecular engineering strategies:
- Fusion Gene Construction: Segments of four major toxins ($\alpha$, $\beta1$, $\beta2$, and $\epsilon$) were fused into a single genetic sequence.
- Genetic Optimization: Codon optimization was performed to align with E. coli’s genetic preferences. Signal peptides were removed to maintain the protein in a soluble state within the cell.
- Safety and Antigenicity: Sequences were selected for high antigenicity while "lethal genes" were removed to ensure safety for both the production host and the vaccine recipient.
- Expression Optimization: To prevent protein clumping, expression was induced at a chilly 16°C with 1 mM IPTG for 16 hours.
- Purification: The protein was purified using Nickel affinity chromatography followed by size-exclusion chromatography.
Results
The study successfully produced a 140 kDa soluble fusion protein. SDS-PAGE analysis confirmed the presence and purity of the protein in the soluble fraction, avoiding the harsh denaturing processes typically required for inclusion bodies.
Immunogenicity trials in mice showed a significant rise in antibody levels, peaking between 6 and 7 weeks post-vaccination. Most importantly, the vaccine provided complete protection against lethal challenges. When immunized mice were exposed to virulent C. perfringens types A, B, C, and D, they achieved a 100% survival rate, whereas all mice in the control group succumbed to the infection.
Discussion and Future Directions
The primary breakthrough of this work is achieving high solubility for a complex multivalent fusion protein. By combining four toxins into one molecule, the manufacturing process is significantly simplified, allowing for a "one-shot" production of a broad-spectrum vaccine. Strategic truncation of the toxins ensured the protein remained water-soluble while retaining high antigenicity.
While these results in mice are promising, further research is needed to translate these findings to target livestock species like cattle, sheep, and pigs. Additionally, future iterations of the vaccine may need to incorporate components for serotype E to provide truly universal protection. Long-term studies are also required to determine the duration of immunity and the necessity of booster doses in a commercial agricultural setting.
Summary updated